PNC-28 (20mg)
A p53-derived research peptide engineered to selectively induce cell death in cancer cells overexpressing HDM-2 on their membrane surface, while sparing normal cells—positioning it as a mechanistically distinct anticancer research tool studied primarily in pancreatic cancer models.
The Science
What is PNC-28?
PNC-28 is a synthetic 18-amino-acid research peptide derived from the MDM-2 binding domain of the p53 tumor suppressor protein (residues 17–26), covalently linked to a penetratin cell-penetrating sequence. The related compound PNC-27 shares the same architecture with a slightly different p53 sequence region. Both peptides were developed to exploit the aberrant membrane expression of HDM-2 (the human MDM-2 homolog) that is observed in many cancer cell types but not in normal cells.
In normal biology, p53 interacts with MDM-2 in the nucleus to regulate its own transcriptional activity and turnover. In cancer cells—particularly those with mutated or non-functional p53—HDM-2 is frequently overexpressed and has been found to localize aberrantly to the plasma membrane. PNC-28 is designed to bind this membrane-expressed HDM-2 and initiate a cell-death process through pore formation in the tumor cell membrane.
Research published in the Annals of Surgical Oncology and the International Journal of Cancer (2006) demonstrated PNC-28's ability to selectively kill pancreatic cancer cells in vitro and inhibit tumor growth in murine xenograft models, without affecting normal pancreatic ductal cells. The proposed mechanism—peptide-induced transmembrane pore formation leading to necrosis rather than apoptosis—has been termed 'poptosis' in subsequent literature.
Laboratory Observations
Research-Observed Areas of Interest
Selective Pancreatic Cancer Cell Killing
In vitro and murine studies demonstrate PNC-28 kills pancreatic cancer cell lines while sparing normal pancreatic ductal epithelial cells—a selectivity attributed to differential membrane HDM-2 expression. Tumor growth inhibition in xenograft models has been published.
Activity Independent of p53 Mutational Status
Because PNC-28's primary mechanism targets membrane-expressed HDM-2 rather than requiring intracellular p53 functionality, it may retain activity in cancer cells with p53 loss-of-function mutations—addressing a major limitation of p53-restoration strategies.
Potential Broad Cancer Cell Applicability
Related research on PNC-27 and PNC-28 analogues has found membrane HDM-2 expression in multiple cancer types beyond pancreatic cancer, including breast, leukemia, and melanoma cell lines—suggesting the targeting principle may extend across tumor types where membrane HDM-2 is expressed.
Novel 'Poptosis' Research Tool
PNC-28's unique membrane-disruption mechanism provides researchers a tool to study a fundamentally different form of cancer cell death distinct from apoptosis, autophagy, or necroptosis—potentially useful in combination regimens or resistance models where apoptotic pathways are blocked.
Mechanism of Action
How PNC-28 Works
PNC-28 selectively targets cancer cells through a three-stage mechanism dependent on differential HDM-2 membrane expression:
Selective Binding to Membrane-Expressed HDM-2
Cancer cells aberrantly express HDM-2 protein on their outer plasma membrane. PNC-28 contains a p53-derived sequence that specifically binds this membrane-associated HDM-2. Because normal cells do not express HDM-2 on their surface in the same manner, this interaction provides the selectivity that distinguishes PNC-28 from general cytotoxic agents.
Transmembrane Pore Formation (Poptosis)
Upon binding membrane-expressed HDM-2, PNC-28 inserts into the lipid bilayer via its penetratin sequence and forms oligomeric pores. These pores disrupt membrane integrity, causing rapid ionic flux, cellular swelling, and necrotic cell death—a process that has been termed 'poptosis' (peptide-induced pore formation). This mechanism is distinct from classical apoptosis and does not require functional intracellular p53.
Penetratin-Mediated Intracellular Delivery (Secondary Mechanism)
PNC-28's penetratin component can also facilitate intracellular delivery of the p53 sequence, where it may interact with intracellular HDM-2, restoring functional p53 activity in cells where p53 is sequestered by overexpressed MDM-2 rather than mutated—a complementary mechanism to the extracellular pore-forming pathway.
FAQ
Frequently Asked Questions
How does PNC-28 differ from conventional chemotherapy?+
Conventional chemotherapy typically targets rapidly dividing cells broadly, causing collateral damage to normal tissues. PNC-28's mechanism is designed to exploit cancer cell-specific membrane HDM-2 expression, theoretically providing selective cancer cell killing while sparing normal cells—though this selectivity has been demonstrated primarily in cell culture and animal models.
What is 'poptosis'?+
Poptosis (peptide-induced transmembrane pore formation) is a cell death mechanism proposed for PNC-27 and PNC-28 whereby the peptide forms membrane pores in cancer cells after binding membrane-expressed HDM-2, causing necrotic cell death. This is distinct from apoptosis, which involves an intracellular enzymatic cascade.
Has PNC-28 been tested in humans?+
No human clinical trial data for PNC-28 have been published. Research remains in the preclinical stage, primarily in cell lines and xenograft mouse models.
What cancers has PNC-28 been studied in?+
Published research has focused primarily on pancreatic cancer models. Related peptides (PNC-27) have been studied in breast cancer and leukemia cell lines, and the targeting principle is being explored more broadly in tumor types that express membrane HDM-2.
Research-Only Notice
PNC-28 (20mg) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.